Qulipta (atogepant) is a prescription drug that’s used to prevent migraine symptoms. Qulipta comes as an oral tablet. Qulipta is used in adults to help prevent symptoms of migraine. This drug ...

Qulipta (atogepant) is AbbVie's second oral CGRP inhibitor after Ubrelvy (ubrogepant) – which was approved for the acute treatment of migraine attacks in 2019 – and rounds out a range that ...

Credit: Getty Images. Only the 60mg dose of Qulipta is indicated for the preventive treatment of chronic migraine. The Food and Drug Administration (FDA) has expanded the approval of Qulipta ...

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronicExpan ...

In 2023, Qulipta (atogepant) generated sales of $408 million, with fourth-quarter 2023 sales of $114 million. Memorial Day Special: Access your full investing command center with trade ideas ...

4 The U.S. Food and Drug Administration recently approved QULIPTA ® as the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist proven to prevent both episodic and ...